IL271759B2 - Pharmaceutical compositions comprising entrectinib - Google Patents

Pharmaceutical compositions comprising entrectinib

Info

Publication number
IL271759B2
IL271759B2 IL271759A IL27175919A IL271759B2 IL 271759 B2 IL271759 B2 IL 271759B2 IL 271759 A IL271759 A IL 271759A IL 27175919 A IL27175919 A IL 27175919A IL 271759 B2 IL271759 B2 IL 271759B2
Authority
IL
Israel
Prior art keywords
difluorobenzyl
indazol
ylamino
piperazin
pyran
Prior art date
Application number
IL271759A
Other languages
English (en)
Hebrew (he)
Other versions
IL271759A (en
IL271759B1 (en
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of IL271759A publication Critical patent/IL271759A/en
Publication of IL271759B1 publication Critical patent/IL271759B1/en
Publication of IL271759B2 publication Critical patent/IL271759B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271759A 2017-07-19 2018-07-18 Pharmaceutical compositions comprising entrectinib IL271759B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762534585P 2017-07-19 2017-07-19
PCT/US2018/042756 WO2019018570A1 (en) 2017-07-19 2018-07-18 PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB

Publications (3)

Publication Number Publication Date
IL271759A IL271759A (en) 2020-02-27
IL271759B1 IL271759B1 (en) 2023-09-01
IL271759B2 true IL271759B2 (en) 2024-01-01

Family

ID=63254769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271759A IL271759B2 (en) 2017-07-19 2018-07-18 Pharmaceutical compositions comprising entrectinib

Country Status (11)

Country Link
US (2) US10398693B2 (https=)
EP (1) EP3654952A1 (https=)
JP (1) JP7203083B2 (https=)
KR (1) KR102718538B1 (https=)
CN (2) CN121401264A (https=)
AU (1) AU2018302170B2 (https=)
BR (1) BR112020000793A2 (https=)
CA (1) CA3069339A1 (https=)
IL (1) IL271759B2 (https=)
TW (1) TWI785074B (https=)
WO (1) WO2019018570A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
AU2020319662B2 (en) 2019-07-31 2024-02-29 F. Hoffmann-La Roche Ag New pharmaceutical formulation
KR20230128086A (ko) * 2020-12-31 2023-09-01 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 다중 표적 단백질 키나아제 억제제의 약학 조성물 및이의 응용
WO2023230454A1 (en) * 2022-05-24 2023-11-30 Icahn School Of Medicine At Mount Sinai Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease
WO2026074301A1 (en) * 2024-10-02 2026-04-09 Meditop Gyógyszeripari Kft Sustained release oral medicinal product containing tolperisone hydrochloride, its production and use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124697A1 (en) * 2014-02-20 2015-08-27 Ignyta, Inc. Compounds for treating patients with ros1 mutant cancer cells
WO2017106492A1 (en) * 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
US5736158A (en) * 1996-03-27 1998-04-07 The Block Drug Company Partial denture cleanser with fluoride
TR200000020T2 (tr) 1997-07-11 2000-09-21 Janssen Pharmaceutica N.V. 5-HT3 ve 5-HT4 aracılı bozuklar için faydalı (+)-norsisaprit.
WO1999043302A1 (en) * 1998-02-27 1999-09-02 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
ATE343575T1 (de) 2001-09-27 2006-11-15 Smithkline Beecham Corp Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003251875A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
BR0314098A (pt) 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm
PL376789A1 (pl) 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2005000786A1 (en) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
DK1675961T3 (da) 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2006080450A1 (ja) 2005-01-27 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Igf-1r阻害剤
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CN101237873A (zh) 2005-08-09 2008-08-06 美因茨约翰内斯古滕贝格大学 用于治疗非小细胞肺癌的星形孢菌素衍生物
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
CN101541788A (zh) 2006-12-11 2009-09-23 Irm责任有限公司 作为激酶抑制剂的化合物和组合物
EP2120932B1 (en) 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Indazole derivatives as kinase inhibitors for the treatment of cancer
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
BRPI0816064B8 (pt) 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
JP2015508644A (ja) 2012-02-08 2015-03-23 インサイト ジェネティクス インコーポレイテッド 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
EP2855460B1 (en) 2012-05-23 2017-11-08 Nerviano Medical Sciences S.r.l. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
CN104968334B (zh) 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
EP2988729A1 (en) * 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3154549A1 (en) 2014-06-13 2017-04-19 Oncoethix GmbH Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2016089853A1 (en) 2014-12-03 2016-06-09 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
JP6929231B2 (ja) 2015-05-29 2021-09-01 イグナイタ インコーポレイテッド Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124697A1 (en) * 2014-02-20 2015-08-27 Ignyta, Inc. Compounds for treating patients with ros1 mutant cancer cells
WO2017106492A1 (en) * 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer

Also Published As

Publication number Publication date
BR112020000793A2 (pt) 2020-07-14
KR102718538B1 (ko) 2024-10-21
EP3654952A1 (en) 2020-05-27
WO2019018570A1 (en) 2019-01-24
CA3069339A1 (en) 2019-01-24
IL271759A (en) 2020-02-27
AU2018302170B2 (en) 2024-02-29
US11253515B2 (en) 2022-02-22
CN121401264A (zh) 2026-01-27
AU2018302170A1 (en) 2020-01-30
US20200163892A1 (en) 2020-05-28
US10398693B2 (en) 2019-09-03
TW201907924A (zh) 2019-03-01
IL271759B1 (en) 2023-09-01
CN110913842A (zh) 2020-03-24
US20190022089A1 (en) 2019-01-24
JP2020527575A (ja) 2020-09-10
JP7203083B2 (ja) 2023-01-12
KR20200031115A (ko) 2020-03-23
TWI785074B (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
US11253515B2 (en) Pharmaceutical compositions and dosage forms
US20210113555A1 (en) Combinations for the treatment of cancer
US20170356918A1 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
US11007191B2 (en) Pharmaceutical compositions and dosage forms
US20190224200A1 (en) Combinations for the treatment of cancer
TW201821078A (zh) 治療癌症之方法
US20220257592A1 (en) Methods of treating cancer
BR122025029354A2 (pt) Método para preparar composição farmacêutica
HK40016507A (en) Pharmaceutical compositions comprising entrectinib
HK40029525B (en) Pharmaceutical compositions and dosage forms
HK40029525A (en) Pharmaceutical compositions and dosage forms